Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
NCT06837896
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
QLG1080
Sponsor
Qilu Pharmaceutical Co., Ltd.